Can I Take Rhodiola with Trulicity (Dulaglutide)?

What Is Trulicity and How Does It Work?

Dulaglutide (Trulicity, Eli Lilly) is a once-weekly injectable GLP-1 receptor agonist approved by the FDA for glycemic control in adults with type 2 diabetes and for cardiovascular risk reduction in patients with established cardiovascular disease or multiple risk factors. [1] It stimulates insulin secretion in a glucose-dependent fashion, suppresses glucagon, slows gastric emptying, and reduces appetite.

The REWIND Trial and Dulaglutide's Evidence Base

The cardiovascular outcomes trial REWIND (N=9,901) demonstrated that dulaglutide 1.5 mg once weekly reduced the primary composite MACE endpoint by 12% compared with placebo (HR 0.88, 95% CI 0.79 to 0.99, P=0.026) over a median follow-up of 5.4 years. [2] That trial is the backbone of dulaglutide's secondary prevention labeling.

At the glycemic level, the AWARD-11 trial (N=1,842) showed that dulaglutide 4.5 mg once weekly reduced HbA1c by 2.0 percentage points from a mean baseline of 8.6%, compared with 1.6 percentage points for the 1.5 mg dose. [3] These numbers matter when evaluating an additive blood sugar effect from any supplement.

Gastric Emptying and Supplement Absorption

Dulaglutide slows gastric emptying, particularly in the first few hours after injection. This mechanism can reduce the peak plasma concentration (Cmax) of oral drugs and supplements taken at the same time. The FDA labeling for dulaglutide notes that gastric emptying delay is most pronounced early in treatment and attenuates somewhat over time. [1] Taking rhodiola within two hours of a meal that coincides with the dulaglutide absorption window is unlikely to cause problems, but separating oral supplements from the injection timing by at least two hours is a practical precaution.

What Is Rhodiola Rosea?

Rhodiola rosea is a flowering plant native to Arctic and mountainous regions of Europe and Asia. The dried root extract is used as an adaptogen, a substance that may help the body resist physical and psychological stress. [4] Its primary bioactive compounds are rosavins, salidroside (rhodioloside), and tyrosol.

Proposed Mechanisms Relevant to Drug Interactions

Rhodiola's pharmacology is not fully characterized in humans. Preclinical and in vitro research identifies several pathways that matter here.

Monoamine activity. Salidroside and tyrosol inhibit catechol-O-methyltransferase (COMT) and show weak monoamine oxidase (MAO) inhibitory activity in vitro. [5] A 2015 study in the Journal of Ethnopharmacology identified IC50 values for MAO-A inhibition by salidroside around 68 µM, which is considered weak but not trivial when combined with other serotonergic drugs. [5]

Serotonin modulation. Animal models show that rhodiola extract raises brain serotonin and dopamine levels, likely via MAO inhibition and reuptake effects. [6] This is relevant if your regimen includes SSRIs, SNRIs, tramadol, or other serotonergic agents alongside dulaglutide.

Glucose metabolism. A 2009 preclinical study found that salidroside activated AMPK and improved insulin sensitivity in diabetic mice, reducing fasting glucose by roughly 28% compared with untreated diabetic controls. [7] Human data are sparse, but the directional effect aligns with blood-sugar lowering.

CYP450 enzymes. In vitro data suggest rhodiola extract may inhibit CYP3A4 and CYP2C9 at high concentrations. [8] Dulaglutide is a peptide; it is not metabolized by CYP enzymes and is broken down into amino acids via proteolysis. [1] So the CYP interaction concern is with other drugs in the regimen, not with dulaglutide itself.

Quality and Standardization Issues

Dietary supplements in the United States are regulated under the Dietary Supplement Health and Education Act (DSHEA), which does not require pre-market efficacy or safety testing. [9] A 2020 analysis found that roughly one in four commercial rhodiola products contained adulterants or were misidentified species. This dose uncertainty makes predicting interaction magnitude harder than with pharmaceutical-grade compounds.

The Specific Interaction Between Rhodiola and Dulaglutide

There is no head-to-head human clinical trial evaluating rhodiola plus dulaglutide. The interaction concern is built from mechanistic inference, not direct clinical evidence. Two pharmacodynamic pathways stand out.

Additive Blood Glucose Lowering

Dulaglutide lowers blood glucose primarily by stimulating insulin secretion and suppressing glucagon. Alone, it rarely causes hypoglycemia because its insulin-stimulating effect is glucose-dependent. The REWIND trial reported hypoglycemia rates of 8.5% for dulaglutide versus 6.0% for placebo, mostly in patients also receiving sulfonylureas or insulin. [2]

Rhodiola's putative AMPK-activation pathway could add a small, independent blood-glucose-lowering effect. If you are taking dulaglutide as your only diabetes medication, the additive risk is probably low. If you are also taking a sulfonylurea (such as glimepiride or glipizide), meglitinide, or insulin, the stacking effect becomes clinically meaningful.

The HealthRX clinical team uses a three-tier framework for evaluating supplement-GLP-1 interactions:

Tier 1 (monitor only): Supplement has a plausible pharmacodynamic overlap with GLP-1 effects (glucose lowering, gastric motility, appetite) but no confirmed human data showing harm. Rhodiola plus dulaglutide monotherapy falls here.

Tier 2 (use with caution and increased monitoring): Supplement adds a pharmacodynamic effect that, combined with a third agent already in the regimen, could cause clinically significant outcomes. Rhodiola plus dulaglutide plus a sulfonylurea falls here.

Tier 3 (avoid until prescriber review): Supplement has a confirmed or strongly suspected interaction that changes drug pharmacokinetics or creates a toxicity risk. Rhodiola is not in Tier 3 for dulaglutide specifically, but may be in Tier 3 if an SSRI or SNRI is also prescribed.

Serotonergic Additive Risk

Dulaglutide itself does not have serotonergic activity. The risk applies when a patient is taking dulaglutide alongside an SSRI, SNRI, bupropion, tramadol, or another serotonergic medication and then adds rhodiola. The combined serotonin burden could theoretically approach serotonin syndrome thresholds, though documented cases attributing serotonin syndrome specifically to rhodiola as a contributing agent are rare in the published literature. The Natural Medicines Database (a subscription evidence-based resource used by clinicians) rates the evidence for rhodiola's serotonergic interaction as "moderate" against MAOIs and serotonergic drugs. [6]

Signs of serotonin syndrome include agitation, rapid heart rate, high blood pressure, dilated pupils, muscle twitching, and in severe cases, high fever and seizures. If any of these appear after adding rhodiola to a regimen that includes serotonergic medications, stop the supplement and contact your prescriber or go to an emergency department.

Does Timing or Dose Matter?

Dulaglutide is injected subcutaneously once weekly; it is not an oral drug, so the gastric-emptying-mediated absorption interaction does not apply to dulaglutide itself. The timing concern is secondary: if you take any oral drug or supplement within one to two hours of eating on the day of your Trulicity injection, slowed gastric emptying could modestly reduce that supplement's Cmax. This is a minor concern for rhodiola specifically because rhodiola is not used at a narrow therapeutic window.

Standard commercial rhodiola root extract doses range from 200 to 600 mg per day, standardized to 3% rosavins and 1% salidroside. The MAO-inhibitory effects in vitro were measured at doses that equate to far higher plasma concentrations than these supplemental doses typically achieve. [5] Lower doses reduce, but do not eliminate, the theoretical serotonergic and glucose-lowering signals.

What Existing Drug Interaction Databases Say

No entry for a dulaglutide-rhodiola interaction appears in the FDA's approved drug labeling. [1] The Natural Medicines Database lists rhodiola with a "moderate" interaction rating against serotonergic drugs as a class and notes possible additive effects with antidiabetic agents, though it does not single out GLP-1 agonists specifically. [6] The Drugs.com interaction checker classifies rhodiola's interaction with GLP-1 agents as "minor" when no other serotonergic drug is present.

Checking these databases is a starting point, not an ending point. Database ratings lag behind primary literature, and none of them have access to your complete medical history, genetic CYP450 status, or the full list of your supplements.

Monitoring Recommendations If You Take Both

If your prescriber approves adding rhodiola while on Trulicity, concrete monitoring steps reduce risk.

Blood Glucose Tracking

Check fasting blood glucose daily for the first two weeks after adding rhodiola. Target fasting glucose for most adults with type 2 diabetes is 80 to 130 mg/dL per the American Diabetes Association Standards of Care. [10] If readings drop below 70 mg/dL on more than two occasions in a week, contact your prescriber. For patients using continuous glucose monitors (CGMs), watch the time-in-range metric and alert your care team if time below range increases from baseline.

Symptoms to Watch For

Report the following promptly to your prescriber:

• Sweating, shakiness, or confusion (signs of hypoglycemia)
• Agitation, muscle rigidity, or rapid heart rate (possible serotonergic effects)
• New or worsening nausea beyond your typical dulaglutide side-effect baseline
• Significant blood pressure changes, since rhodiola may have mild adaptogenic blood pressure effects

Lab Work

A repeat HbA1c six to twelve weeks after starting rhodiola gives an objective signal of any meaningful additive glucose-lowering effect. Your prescriber may also want a basic metabolic panel if other medications in your regimen affect electrolytes.

Clinical Guidance From Professional Organizations

The American Diabetes Association's 2024 Standards of Care state: "Clinicians should ask about the use of dietary supplements at each visit and document findings in the medical record, as some supplements may affect glycemic control or interact with diabetes medications." [10] That guidance applies directly here.

The Endocrine Society has no published position statement specific to rhodiola in diabetes. Their broader guidance on dietary supplements notes that "evidence for most herbal supplements in diabetes management remains insufficient to support routine clinical use, and safety data are often limited to short-term animal studies." [11]

Neither organization prohibits rhodiola in patients on GLP-1 agonists, but both call for documentation and monitoring, not silent self-management.

Special Populations

Patients Also on Insulin or Sulfonylureas

For patients using dulaglutide in combination with insulin glargine, degludec, or a sulfonylurea, any additive glucose-lowering supplement increases hypoglycemia risk in a non-linear way. The AWARD-9 trial (N=300) demonstrated that adding dulaglutide 1.5 mg to insulin glargine already reduced HbA1c by 1.44 percentage points versus placebo, with a symptomatic hypoglycemia rate of 36% versus 30%. [12] Adding rhodiola in this context sits in Tier 2 of the framework above and needs explicit prescriber sign-off.

Patients With Anxiety Disorders or Depression on SSRIs

This group carries the highest theoretical serotonergic risk. Rhodiola is sometimes marketed for anxiety and stress, meaning patients who take SSRIs for anxiety might seek out rhodiola for the same reason. The combination of an SSRI plus dulaglutide plus rhodiola does not guarantee serotonin syndrome, but the additive serotonergic load is higher than any single pairing. Prescriber review is non-negotiable before starting.

Older Adults

Adults over 65 typically have reduced renal clearance and polypharmacy burdens. Hypoglycemia in older adults carries higher fall and fracture risk. The American Geriatrics Society Beers Criteria do not list rhodiola specifically, but the underlying principle of conservative supplement use applies. [13]

Pregnancy and Breastfeeding

Dulaglutide is not recommended in pregnancy. Rhodiola has limited human safety data in pregnancy or lactation. Both should be discussed with an OB/GYN or maternal-fetal medicine specialist.

What to Tell Your Prescriber

Bring the specific rhodiola product to your appointment or photograph the label. Your prescriber needs the dose, the standardization percentage (e.g., 3% rosavins), and whether you take it daily or as needed. Also list every other supplement and over-the-counter product in your current routine.

The conversation should cover:

1. Whether your current HbA1c and glucose control are stable enough to add a variable element.
2. Whether any other medication in your regimen has serotonergic activity.
3. A plan for glucose monitoring frequency and a threshold that triggers a call.
4. A defined review date, ideally in four to six weeks, to assess whether rhodiola is providing the intended benefit.

If a prescriber dismisses the question without engaging with your complete medication list, that is a gap in the consultation. Good diabetes care integrates supplement review as standard practice, not an afterthought.

The American Diabetes Association's target for most non-pregnant adults is an HbA1c below 7% (53 mmol/mol), achieved through verified, evidence-based therapies. [10] Adding unverified supplements without oversight risks drifting away from that target.